SecBot SecBot
Biotech Drug Report Generated Oct 28, 2026

VUMERITY

BIIB·BIOGEN INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available since October 2019.
Why 4/10
VUMERITY is already FDA-approved and commercially marketed with no pending PDUFA date, pivotal readout, or regulatory decision scheduled in the next 12 months. As an approved drug without a binary catalyst, the impact score defaults to 4 per the rubric.
Actionable Insight NEUTRAL

VUMERITY has no upcoming FDA catalyst; the next material event for Biogen is the litifilimab Phase 3 SLE readout expected in December 2026. For VUMERITY specifically, watch quarterly sales trends and any generic patent challenges as the 2033 loss-of-exclusivity date approaches.

Price Chart

Loading chart...

Executive Summary

VUMERITY (diroximel fumarate) is an FDA-approved oral therapy for relapsing forms of multiple sclerosis, developed by Biogen (BIIB) in partnership with Alkermes. Approved in 2019 as a next-generation follow-up to Biogen's Tecfidera, it offers improved gastrointestinal tolerability. In Q3 2026, VUMERITY generated $192M in in-market sales, down 11% year-over-year, reflecting ongoing pressure on Biogen's MS franchise from generic Tecfidera competition and payer dynamics. A June 2026 real-world study showed fewer MS relapses with VUMERITY versus Tecfidera, providing a potential differentiation point. Patent protection extends to 2033, with no generic diroximel fumarate currently on the market. VUMERITY is a modest contributor to Biogen's Growth Portfolio, which is increasingly driven by newer products like SPINRAZA, LEQEMBI, and SYFOVRE.

How It Works

VUMERITY is an oral capsule taken twice daily for relapsing forms of multiple sclerosis. Once swallowed, the body rapidly converts it into monomethyl fumarate, the same active molecule. While the exact mechanism is not fully understood, it is thought to reduce inflammation and activates antioxidant response genes, which helps reduce MS relapses and delays disability progression. It is a next-generation version of Biogen's older drug Tecfidera, designed to cause fewer gastrointestinal side effects.

Trial Status

VUMERITY was approved by the FDA in October 2019 via the 505(b)(2) pathway based on pharmacokinetic bridging studies showing bioequivalence to Tecfidera. A Phase 3 EVOLVE-MS-2 study demonstrated improved gastrointestinal tolerability versus Tecfidera. An ongoing observational study (NCT05767736) is evaluating long-term safety in over 10,000 patients. A June 2026 real-world study found significantly lower MS relapse rates with VUMERITY versus Tecfidera.

The Two-Sided Case

▲ Bull Case4
A real-world study published June 2026 found significantly lower MS relapse rates with VUMERITY versus Tecfidera, providing a clinical differentiation argument for physicians and payers.
VUMERITY was designed with improved gastrointestinal tolerability compared to Tecfidera, a key differentiator that supports patient adherence and switching.
Patent protection runs until at least 2033, with no generic diroximel fumarate currently on the market, giving Biogen several more years of exclusivity.
VUMERITY is classified in Biogen's Growth Portfolio, which generated $1.26B in Q3 2026 (up 49% YoY), showing the company is successfully rotating toward newer products.
▼ Bear Case4
VUMERITY Q3 2026 in-market sales fell 11% year-over-year to $192M, continuing a declining trend as the MS franchise faces payer pressure.
Tecfidera (dimethyl fumarate) has 17 AB-rated generic competitors in the U.S., creating extreme price competition in the fumarate class that pressures VUMERITY's pricing power.
Biogen's overall MS product revenue declined 13.4% YoY in Q3 2026, showing the broader erosion of the legacy MS portfolio.
VUMERITY's foundational composition patent expires in 2033, with generic entry expected around that time, limiting long-term exclusivity.

Upcoming Catalysts

  • No upcoming FDA catalyst specific to VUMERITY. The drug is already approved and marketed. Watch quarterly sales trends for continued erosion or stabilization.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOGEN INC. 8-K BIIB ·Originating report

Sources · 10

Hover a chip for the title
1 investors.biogen.com2 drugs.com3 multiplesclerosisnewstoday.com4 sec.gov5 investors.com6 drugs.com7 pharsight.greyb.com8 pharmadossier.com9 en.wikipedia.org10 sa.marketscreener.com